TY - JOUR
T1 - GFAT2 mediates cardiac hypertrophy through HBP-O-GlcNAcylation-Akt pathway
AU - Ishikita, Akihito
AU - Matsushima, Shouji
AU - Ikeda, Soichiro
AU - Okabe, Kosuke
AU - Nishimura, Ryohei
AU - Tadokoro, Tomonori
AU - Enzan, Nobuyuki
AU - Yamamoto, Taishi
AU - Sada, Masashi
AU - Tsutsui, Yoshitomo
AU - Miyake, Ryo
AU - Ikeda, Masataka
AU - Ide, Tomomi
AU - Kinugawa, Shintaro
AU - Tsutsui, Hiroyuki
N1 - Funding Information:
We are very grateful to A. Hanada and M. Sato for technical support. We also appreciate the technical assistance from the Research Support Center, Faculty of Medical Sciences, Kyushu University. This work was supported by Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Nos. 17K09581, 19K22622, and 19H03655) and Vascular Biology Innovation Conference (VBIC). A.I. and S.M. designed the research. A.I. S.I. K.O. N.E. T.Y. M.S. and Y.T. performed in vivo experiments. A.I. S.I. R.N. T.T. and R.M. performed in vitro experiments. A.I. S.M. M.I. T.I. and H.T. analyzed data. M.I. T.I. S.K. and H.T. provided guidance on experimental designs and data analyses. A.I. and S.M. wrote the manuscript. All authors provided feedback on the manuscript. The authors declare that they have no competing interests.
Funding Information:
We are very grateful to A. Hanada and M. Sato for technical support. We also appreciate the technical assistance from the Research Support Center, Faculty of Medical Sciences, Kyushu University. This work was supported by Japan Society for the Promotion of Science ( JSPS ) KAKENHI (Grant Nos. 17K09581 , 19K22622 , and 19H03655 ) and Vascular Biology Innovation Conference (VBIC).
Publisher Copyright:
© 2021 The Authors
PY - 2021/12/17
Y1 - 2021/12/17
N2 - Molecular mechanisms mediating cardiac hypertrophy by glucose metabolism are incompletely understood. Hexosamine biosynthesis pathway (HBP), an accessory pathway of glycolysis, is known to be involved in the attachment of O-linked N-acetylglucosamine motif (O-GlcNAcylation) to proteins, a post-translational modification. We here demonstrate that glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2), a critical HBP enzyme, is a major isoform of GFAT in the heart and is increased in response to several hypertrophic stimuli, including isoproterenol (ISO). Knockdown of GFAT2 suppresses ISO-induced cardiomyocyte hypertrophy, accompanied by suppression of Akt O-GlcNAcylation and activation. Knockdown of GFAT2 does not affect anti-hypertrophic effect by Akt inhibition. Administration of glucosamine, a substrate of HBP, induces protein O-GlcNAcylation, Akt activation, and cardiomyocyte hypertrophy. In mice, 6-diazo-5-oxo-L-norleucine, an inhibitor of GFAT, attenuates ISO-induced protein O-GlcNAcylation, Akt activation, and cardiac hypertrophy. Our results demonstrate that GFAT2 mediates cardiomyocyte hypertrophy by HBP-O-GlcNAcylation-Akt pathway and could be a critical therapeutic target of cardiac hypertrophy.
AB - Molecular mechanisms mediating cardiac hypertrophy by glucose metabolism are incompletely understood. Hexosamine biosynthesis pathway (HBP), an accessory pathway of glycolysis, is known to be involved in the attachment of O-linked N-acetylglucosamine motif (O-GlcNAcylation) to proteins, a post-translational modification. We here demonstrate that glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2), a critical HBP enzyme, is a major isoform of GFAT in the heart and is increased in response to several hypertrophic stimuli, including isoproterenol (ISO). Knockdown of GFAT2 suppresses ISO-induced cardiomyocyte hypertrophy, accompanied by suppression of Akt O-GlcNAcylation and activation. Knockdown of GFAT2 does not affect anti-hypertrophic effect by Akt inhibition. Administration of glucosamine, a substrate of HBP, induces protein O-GlcNAcylation, Akt activation, and cardiomyocyte hypertrophy. In mice, 6-diazo-5-oxo-L-norleucine, an inhibitor of GFAT, attenuates ISO-induced protein O-GlcNAcylation, Akt activation, and cardiac hypertrophy. Our results demonstrate that GFAT2 mediates cardiomyocyte hypertrophy by HBP-O-GlcNAcylation-Akt pathway and could be a critical therapeutic target of cardiac hypertrophy.
UR - http://www.scopus.com/inward/record.url?scp=85120819706&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120819706&partnerID=8YFLogxK
U2 - 10.1016/j.isci.2021.103517
DO - 10.1016/j.isci.2021.103517
M3 - Article
AN - SCOPUS:85120819706
SN - 2589-0042
VL - 24
JO - iScience
JF - iScience
IS - 12
M1 - 103517
ER -